RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy.
about
Receptor for advanced glycation end products and its involvement in inflammatory diseasesCirculating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune DiseasesRole of Neuropilin-1 in Diabetic NephropathyMolecular mechanisms of diabetic kidney diseaseThe -374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patientsRAGE and CYBA polymorphisms are associated with microalbuminuria and end-stage renal disease onset in a cohort of type 1 diabetes mellitus patients over a 20-year follow-upA role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosiscAMP ameliorates inflammation by modulation of macrophage receptor for advanced glycation end-productsThe multiple faces of RAGE--opportunities for therapeutic intervention in aging and chronic diseaseMicroglial receptor for advanced glycation end product-dependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex.Dangers within: DAMP responses to damage and cell death in kidney disease.The sour side of neurodegenerative disorders: the effects of protein glycation.Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis.Molecular mechanisms of diabetic vascular complicationsControlling the receptor for advanced glycation end-products to conquer diabetic vascular complicationsRAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer.The glomerulus--a view from the outside--the podocyte.Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse.Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and agingLocal and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAHObesity in kidney disease: A heavyweight opponent.C-peptide and diabetic kidney disease.Modulation of the cellular expression of circulating advanced glycation end-product receptors in type 2 diabetic nephropathy.Promoting effects of the adipokine, apelin, on diabetic nephropathy.-374 T/A RAGE polymorphism is associated with chronic kidney disease progression in subjects affected by nephrocardiovascular disease.Paradoxical function for the receptor for advanced glycation end products in mouse models of pulmonary fibrosis.Messenger RNA levels of podocyte-associated proteins in subjects with different degrees of glucose tolerance with or without nephropathyAlternative splicing of the RAGE cytoplasmic domain regulates cell signaling and function.RAGE signaling significantly impacts tumorigenesis and hepatic tumor growth in murine models of colorectal carcinoma.New insight into the molecular drug target of diabetic nephropathy.Regulation of RAGE for attenuating progression of diabetic vascular complications.Growth factors and the development of diabetic nephropathy.Mechanisms and consequences of TGF-ß overexpression by podocytes in progressive podocyte disease.Use of genetic mouse models in the study of diabetic nephropathy.Sesamin Ameliorates Advanced Glycation End Products-Induced Pancreatic β-Cell Dysfunction and Apoptosis.Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics.Antiproteinuric effect of RAS blockade: new mechanisms.Role of advanced glycation end products in cardiovascular disease.RAGE and TGF-β1 Cross-Talk Regulate Extracellular Matrix Turnover and Cytokine Synthesis in AGEs Exposed Fibroblast Cells
P2860
Q21285070-C670234A-66DE-499D-B64C-6B36F5416353Q26768480-59D7D8DE-E13E-42AD-B2BA-5FC266916778Q26799448-BC330AF8-95A5-4E21-BF00-4AE8C7BDC2B0Q27003963-65D3891C-42E8-4B01-AB61-97085E8B2F8DQ28263324-21CACBE6-F73A-415C-BCC3-7E3230E1F6B9Q28270272-E52F6ED0-A8D5-465B-BA29-1C9C483538EFQ28507626-BFEBF881-12CC-4B5F-84E4-DE17811947E1Q28587417-DD714F08-2981-40CD-8974-6250CC374793Q28830568-93DDFA00-47F7-4BDB-8726-C5E673A0CF70Q30090185-8FF8D840-1098-4941-89C3-FA71E54396E6Q30380000-F9576DD1-FFDD-4CFC-824E-E6686ED67CEBQ30386079-905D1774-94CA-4B7E-BBC9-7E4DCA45719BQ33367473-4DE1DFA9-BB07-4F08-8823-79B2EB500B07Q33558421-D6291DA2-7E9D-4292-A326-39CC7F188D71Q33609776-328616B7-18D9-455E-BC11-2AC89096DA24Q33726461-00AB192F-6E26-4380-AA69-25720A3C0832Q34020798-DD1B5882-003F-4A4F-9C9A-5691DC6B0882Q34024272-D8CEE391-115A-469C-9A5F-08C09390922DQ34024334-C3605364-D6E9-4EBC-9C92-A4160B37AB3CQ34094369-8FA612B5-CA87-464B-B8D2-BA45E3135935Q34133874-E2D811C0-C017-424A-8581-C7417E4BEAD6Q34367664-0FE6AECB-514E-4417-B3CA-F5949DC7D430Q34540591-8DB78679-16B5-4529-802B-3A1FCF7F3C35Q34557348-B5D7EC55-DF04-4BBC-9328-61F6CE863335Q34663765-2210487C-C4CE-4C84-9FAA-DCF07C3ED99DQ34672674-63285A60-29BD-4823-BC86-55E9FD8DDB48Q34766912-86EF6E9C-8C80-4FF5-BF20-8870D3634239Q35011234-8C645D16-AB63-4EE0-888A-D41EC3D17046Q35048039-705065DC-1C14-4301-B6E9-D0B7B4F20190Q35102969-647BA563-4F47-4BA7-9958-EE5665F54E46Q35125585-BF9878EA-A0DF-4673-968D-34434AC202CDQ35494903-5BC61E90-1C70-4D7C-93DD-4C8C9C140609Q35581294-E6E89489-2ABE-42A8-BF65-4E896ADF2FD6Q35649310-B7402527-2D55-4FD0-960B-14EB807463BFQ35739805-719628FE-81F6-4B31-970A-47D8A188A99AQ35808979-67F0CCEF-5FD7-4B5E-A262-8A81CBD7C1D6Q35809946-28D6F19B-05B1-4559-9295-6FD583AACED1Q35876457-F2B9E7CE-4C18-43FB-987A-973914FB0242Q35929112-F4B57569-22F0-473B-A041-BF0E867D73CFQ35970395-3E5FA249-5DE3-4DF7-B940-75315B04AAA5
P2860
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
RAGE drives the development of ...... nesis of diabetic nephropathy.
@en
RAGE drives the development of ...... nesis of diabetic nephropathy.
@nl
type
label
RAGE drives the development of ...... nesis of diabetic nephropathy.
@en
RAGE drives the development of ...... nesis of diabetic nephropathy.
@nl
prefLabel
RAGE drives the development of ...... nesis of diabetic nephropathy.
@en
RAGE drives the development of ...... nesis of diabetic nephropathy.
@nl
P2093
P2860
P1476
RAGE drives the development of ...... nesis of diabetic nephropathy.
@en
P2093
Angelika Bierhaus
Ann Marie Schmidt
Bernd Arnold
Bernhard Moser
Birgit Liliensiek
David M Stern
Glen S Markowitz
Gunther Stein
Jiancheng Guo
Ling Ling Rong
P2860
P304
P356
10.1016/S0002-9440(10)63909-0
P407
P577
2003-04-01T00:00:00Z